Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a...
Vaccine
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products...
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology...
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research...
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing...
Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections
First-in-human study for ETH47 to evaluate safety, tolerability, and target engagement in healthy participantsMUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE)...
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing...
Bavarian Nordic to hold Capital Markets Days in February 2024
COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in...
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for...
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI),...
Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)
ORION CORPORATION PRESS RELEASE 20 NOVEMBER 2023 at 15.00 EET Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen...
Gritstone bio to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023...
Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major...
NanoViricides Has Filed its Quarterly Report – NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for...
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second...